{"ticker": {"uuid": "f6f0f4bb-36d0-4f62-9ce6-3448de0bbb97", "symbol": "RIGL", "name": "Rigel Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQaUl0VEFNeThOTThJcVFkTXM3VW9TYzVnNTVDakwxcTN2N0Z0aTl3clZqd1VYVlJfbmdTTjlBcjFJRkpRbElSdXhnWUtPZ3JrTGZ1UTBPM2ozOVdyMU9UanpMU1ZIOWRoa1VObnYtT0tZMjRGTkJIMGdGZzZ0NnVKekRrMFlZbi1LeGpxTWFSRF8zNDlHMEI0S2JB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-20T11:44:13+00:00", "published_display": "20 Jun 2026 11:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (RIGL) Price Events", "summary": "This article from Stock Traders Daily analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models to provide trading strategies and signals. It details key findings including sentiment analysis, risk-reward scenarios, and support/resistance levels across different time hor", "url": "https://news.stocktradersdaily.com/news_release/149/Liquidity_Mapping_Around_RIGL_Price_Events_062026011402_1781932442.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T01:14:00", "published_display": "20 Jun 2026 01:14", "sentiment": "positive", "sentiment_pct": 75, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Expands Oncology Portfolio with VEPPANU Global Rights", "summary": "Rigel Pharmaceuticals has acquired exclusive global rights for VEPPANU (vepdegestrant) through an agreement with Arvinas, Inc. and Pfizer Inc. This $70 million upfront payment expands Rigel's oncology pipeline. While analysts rate RIGL stock a \"Buy\" with a $57.00 target, TipRanks", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RIGL-Q/pressreleases/2546395/rigel-expands-oncology-portfolio-with-veppanu-global-rights/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T12:38:57", "published_display": "19 Jun 2026 12:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Rigel Pharmaceuticals Inc (RIGL), noting its strong financial status and high operating efficiency. The company's current financial score is 7.99, placing it well within the pharmaceuticals industry. Rigel recently reported a 1", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rigl/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:39", "published_display": "18 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey reports on Rigel Pharmaceuticals Inc (RIGL), noting its current stock price, market capitalization, and P/E ratio. The primary focus of the article is the company's revenue breakdown; however, it states that relevant data for business segments, region", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rigl/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T14:10:48", "published_display": "17 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart\u2013Scott\u2013Rodino Antitrust Improv", "summary": "Arvinas Holding Company LLC, Pfizer, and Rigel Pharmaceuticals have received approval under the Hart\u2013Scott\u2013Rodino Antitrust Improvements Act on June 11, 2026. This approval removes regulatory hurdles for their previously announced licensing agreement, allowing them to advance the", "url": "https://www.bitget.com/amp/news/detail/12560605463270", "source_name": "Bitget", "published_at": "2026-06-16T23:10:48", "published_display": "16 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Closes Licensing Deal for Breast Cancer Drug Veppanu", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rigel-pharmaceuticals-closes-licensing-deal-203103036.html", "source_name": "MT Newswires", "published_at": "2026-06-16T20:31:03+00:00", "published_display": "16 Jun 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel pays $70M for rights to FDA-approved breast cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPcTZocVRjX2dsT0w4cG4zbkZCUlZkNldScURUZ29tMFF2MmFDaFlpQjNvcDA0TlBIaGxwM3dsTGxZTWZCZFMxQUhWTFdrOVJpMi1hcWdlY2lkeE03LUxXQUxQVGQ2MWJxcF8zOUc3VGtMa3lSaEx3dXdTUnlJbldVNExob25QUWJkNVJKZFc5OHluVU5ocUxYOElfRXJIRjFzZko3bDJQQjBpNmlUQlJ5UWUyZDBSQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T20:01:00+00:00", "published_display": "16 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Announces Closing of Licensing Agreement for VEPPANU\u2122 (vepdegestrant)", "summary": "Rigel Pharmaceuticals, Inc. announced the closing of its licensing agreement for VEPPANU\u2122 (vepdegestrant) with Arvinas, Inc. and Pfizer Inc. The agreement, effective as of June 11, 2026, followed the early termination of the Hart-Scott Rodino waiting period. Rigel made an upfront", "url": "https://www.prnewswire.com/news-releases/rigel-announces-closing-of-licensing-agreement-for-veppanu-vepdegestrant-302802278.html", "source_name": "PR Newswire", "published_at": "2026-06-16T20:10:31", "published_display": "16 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (RIGL) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) stock, highlighting a neutral near and mid-term outlook but a strong long-term positive bias. It presents several AI-generated trading strategies, including long, momentum breakout, and short options, along with key ", "url": "https://news.stocktradersdaily.com/news_release/151/Why_RIGL_Price_Action_Is_Critical_for_Tactical_Trading_060926120602_1780977962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-09T00:06:00", "published_display": "09 Jun 2026 00:06", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel Pharmaceuticals", "summary": "Dean Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals, exercised stock options worth $52,271 for 3,381 shares. The company shows positive revenue growth of 10.28% and a high gross margin of 92.17%, but struggles with a high debt-to-equity ratio of 0.11. The article", "url": "https://www.benzinga.com/insights/news/26/06/53004684/insider-move-dean-schorno-exercises-options-realizing-52k-at-rigel-pharmaceuticals", "source_name": "Benzinga", "published_at": "2026-06-04T15:09:09", "published_display": "04 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGEL (RIGL) EVP Furey uses 877 shares to cover tax obligations", "summary": "RIGEL PHARMACEUTICALS INC EVP Raymond J. Furey reported a tax-withholding disposition of 877 common shares on June 1, 2026, at $29.86 per share to cover tax obligations. This non-market transaction is classified as a routine tax-withholding disposition, not a discretionary sale. ", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-411113e66737.html", "source_name": "Stock Titan", "published_at": "2026-06-04T06:10:28", "published_display": "04 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (NASDAQ: RIGL) EVP uses shares to cover tax obligations", "summary": "Rigel Pharmaceuticals EVP and Chief Commercial Officer, David A. Santos, reported a tax-related share disposition. He delivered 874 shares of common stock at $29.86 per share to cover tax obligations, which is a routine tax-withholding event, not an open-market sale. After this t", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-52243dba54e5.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:40:59", "published_display": "03 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (RIGL) CMO uses 850 shares to cover stock tax liability", "summary": "Rigel Pharmaceuticals Inc.'s EVP and Chief Medical Officer, Lisa Rojkjaer, disposed of 850 shares of common stock on June 1, 2026, to cover a tax liability. This transaction, valued at $29.86 per share, was a tax-withholding disposition, not an open-market sale or purchase. After", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-3f0e77093995.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:40:59", "published_display": "03 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) CFO exercises options and withholds shares for taxes", "summary": "Rigel Pharmaceuticals' EVP & Chief Financial Officer, Dean L. Schorno, exercised stock options for 3,381 shares and withheld 928 shares to cover tax obligations. This transaction was a tax-withholding event, not an open-market sale, leaving him with 78,790 directly held shares. A", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-cdac36f714e3.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:40:59", "published_display": "03 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake", "summary": "RIGEL PHARMACEUTICALS INC CEO Raul R. Rodriguez reported a Form 4 transaction where 2,424 shares of Common Stock were delivered on June 1, 2026, at $29.86 per share to cover tax obligations. This disposition is classified as routine tax withholding, not an open-market trade. Foll", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-1f5e715e5c76.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:40:59", "published_display": "03 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (NasdaqGS:RIGL) Stock Forecast & Analyst Predictions", "summary": "Rigel Pharmaceuticals (RIGL) is facing a forecast decline in earnings (33.2% per annum) and EPS (43.2% per annum) over the next three years, despite expected annual revenue growth of 6.9%. The company recently acquired global rights to the breast cancer therapy VEPPANU, which is ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rigl/rigel-pharmaceuticals/future", "source_name": "Simply Wall Street", "published_at": "2026-06-02T07:39:34", "published_display": "02 Jun 2026 07:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGL - Expansion And Clinical Pipeline Will Drive Future Opportunities Despite Risks", "summary": "Rigel Pharmaceuticals' future opportunities are driven by the expansion of its commercial portfolio and a diversified clinical pipeline, despite risks from product dependence and competition. Analysts have lifted their price target due to updated assumptions around long-term reve", "url": "https://simplywall.st/narratives/86r9h1hu-expansion-and-clinical-pipeline-will-drive-future-opportunities-despite-risks-3puf?bpId=4467656&link_type=cta_narrative_prompt_after_quote", "source_name": "Simply Wall Street", "published_at": "2026-05-29T20:10:00", "published_display": "29 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) director sells 2,500 shares in open-market trade", "summary": "Rigel Pharmaceuticals director Ali-Jackson Kamil sold 2,500 shares of common stock at an average price of $29.17 per share on May 26, 2026. This open-market transaction falls under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following the sale, the director ", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-5cd7f5724ada.html", "source_name": "Stock Titan", "published_at": "2026-05-29T02:39:45", "published_display": "29 May 2026 02:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Phar", "summary": "Kamil Ali-jackson, a Director at Rigel Pharmaceuticals Inc (RIGL), sold 2,500 shares of the company on May 26, 2026, reducing her holdings to 12,625 shares. This sale is part of a trend with no insider buys and two insider sells for RIGL over the last year. The stock is currently", "url": "https://www.gurufocus.com/news/8889885/insider-sell-kamil-alijackson-sells-2500-shares-of-rigel-pharmaceuticals-inc-rigl", "source_name": "GuruFocus", "published_at": "2026-05-29T02:39:45", "published_display": "29 May 2026 02:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (RIGL)", "summary": "Quantitative analysis for Rigel Pharmaceuticals Inc. (RIGL) shows strong sentiment across all horizons, supporting an overweight bias. The article details three trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, and stop-loss levels, ind", "url": "https://news.stocktradersdaily.com/news_release/8/Understanding_Momentum_Shifts_in_RIGL_052826103602_1780022162.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-28T22:39:45", "published_display": "28 May 2026 22:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock", "summary": "Rigel Pharmaceuticals director Ali-Jackson Kamil sold 2,500 shares of the company's common stock for a total of $72,925 on May 26, 2026. This transaction was conducted under a pre-arranged 10b5-1 trading plan. The company recently reported a 26% revenue increase in Q1 2026 and se", "url": "https://www.investing.com/news/insider-trading-news/rigel-pharmaceuticals-director-alijackson-kamil-sells-72925-in-stock-93CH-4715431", "source_name": "Investing.com", "published_at": "2026-05-28T20:39:45", "published_display": "28 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) CEO to Present at Jefferies Global Healthcare Conference", "summary": "Rigel Pharmaceuticals (RIGL) CEO, Raul Rodriguez, will present at the Jefferies Global Healthcare Conference on June 3, 2026, to highlight the company's advancements in biotechnology. While the stock is currently slightly overvalued according to its GF Value, its GF Score of 78 i", "url": "https://www.gurufocus.com/news/8886111/rigel-pharmaceuticals-rigl-ceo-to-present-at-jefferies-global-healthcare-conference", "source_name": "GuruFocus", "published_at": "2026-05-27T20:10:22", "published_display": "27 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel to Present at the Jefferies Global Healthcare Conference", "summary": "Rigel Pharmaceuticals, Inc. announced that its President and CEO, Raul Rodriguez, will present a company overview at the Jefferies Global Healthcare Conference. The presentation is scheduled for Wednesday, June 3, 2026, at 8:45 a.m. ET in New York. A live webcast and archived rec", "url": "https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-global-healthcare-conference-302782544.html", "source_name": "PR Newswire", "published_at": "2026-05-27T12:09:46", "published_display": "27 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech CEO to give Rigel company overview at Jefferies healthcare conference", "summary": "Rigel Pharmaceuticals (Nasdaq: RIGL) announced that its President and CEO, Raul Rodriguez, will present a company overview at the Jefferies Global Healthcare Conference on June 3, 2026, in New York. The presentation will be webcast live and available for replay on Rigel's investo", "url": "https://www.stocktitan.net/news/RIGL/rigel-to-present-at-the-jefferies-global-healthcare-ujsko29u2p65.html", "source_name": "Stock Titan", "published_at": "2026-05-27T12:09:46", "published_display": "27 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] RIGEL PHARMACEUTICALS INC SEC Filing", "summary": "This article details an SEC Form 144 filing by RIGEL PHARMACEUTICALS INC (RIGL) regarding a proposed sale of securities. The filing indicates a sale of 2,500 common shares by an individual with an aggregate market value of $72,925.00, acquired through restricted stock vesting as ", "url": "https://www.stocktitan.net/sec-filings/RIGL/144-rigel-pharmaceuticals-inc-sec-filing-ec0529825ef2.html", "source_name": "Stock Titan", "published_at": "2026-05-26T14:40:13", "published_display": "26 May 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress", "summary": "Rigel Pharmaceuticals, Inc. announced upcoming oral and poster presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress, showcasing data for GAVRETO\u00ae (pralsetinib) and REZLIDHIA\u00ae (olutasidenib). The presentations will include final data from the Phase 3 AcceleRET-Lung c", "url": "https://www.prnewswire.com/news-releases/rigel-announces-oral-and-poster-presentations-at-the-2026-asco-annual-meeting-and-eha2026-congress-302779594.html", "source_name": "PR Newswire", "published_at": "2026-05-21T21:40:16", "published_display": "21 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer\u2019s VEPPANU License With Rigel Adds New Angle To PFE Story", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pfizer-veppanu-license-rigel-adds-051231627.html", "source_name": "Simply Wall St.", "published_at": "2026-05-21T05:12:31+00:00", "published_display": "21 May 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGEL (NASDAQ: RIGL) director receives 5,750-share Restricted Stock Unit grant", "summary": "RIGEL Pharmaceuticals Inc. director Alison L. Hannah received a grant of 5,750 Restricted Stock Units (RSUs) as a compensation-related award, not a market purchase. These RSUs, which represent common stock shares, will fully vest on the day before the company's next Annual Meetin", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-3797d04e0321.html", "source_name": "Stock Titan", "published_at": "2026-05-20T23:40:17", "published_display": "20 May 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. (RIGL) M&A Call - Slideshow (NASDAQ:RIGL) 2026-05-20", "summary": "Rigel Pharmaceuticals, Inc. published a slide deck in conjunction with an M&A call on May 20, 2026. This article was written by SA Transcripts, Seeking Alpha's team responsible for thousands of quarterly earnings call transcripts. The team aims to share new transcript-related dev", "url": "https://seekingalpha.com/article/4907281-rigel-pharmaceuticals-inc-rigl-m-and-a-call-slideshow?source=generic_rss", "source_name": "Seeking Alpha", "published_at": "2026-05-20T23:39:50", "published_display": "20 May 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (RIGL) investors back equity plan, ESPP and auditor at 2026 meeting", "summary": "Rigel Pharmaceuticals stockholders approved amendments to the 2018 Equity Incentive Plan and the 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares respectively for future grants and purchases. All three director nominees were elected to serve until the 2029 ann", "url": "https://www.stocktitan.net/sec-filings/RIGL/8-k-rigel-pharmaceuticals-inc-reports-material-event-f5e1088adc77.html", "source_name": "Stock Titan", "published_at": "2026-05-20T20:10:53", "published_display": "20 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (NASDAQ: RIGL) director awarded 5,750 RSUs vesting before annual meeting", "summary": "Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) director Michael Patrick Miller was granted 5,750 Restricted Stock Units (RSUs) as compensation, which will vest fully before the company's next Annual Meeting, provided he continues his service on the Board. This transaction, detailed in", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-2be0f5f35644.html", "source_name": "Stock Titan", "published_at": "2026-05-20T12:10:53", "published_display": "20 May 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rigel-pharmaceuticals-inks-breast-cancer-203107776.html", "source_name": "Benzinga", "published_at": "2026-05-15T20:31:07+00:00", "published_display": "15 May 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA\u2011Approved Breast Cancer Drug VEPPANU", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rigel-present-2026-rbc-capital-120500026.html", "source_name": "PR Newswire", "published_at": "2026-05-14T12:05:00+00:00", "published_display": "14 May 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rigel-pharmaceuticals-rigl-20-5-061326997.html", "source_name": "Simply Wall St.", "published_at": "2026-05-14T06:13:26+00:00", "published_display": "14 May 2026 06:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breast cancer drug VEPPANU shifts to Rigel in $85M Arvinas-Pfizer deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNcEZEeEw3bF9WMjhZRWZlWGVFMHFVWEtSSGcyUm9GaTQ2SmZMWkwtU2pDWDBzRVdWbVE2QVF5NTZFdFVBN3ZReTBPZ2szRmhFWThDcmR0RHNoQzE1U0Rwc3JfSkxkWTctcU9UR3JHeHJwc2dDamxUeVVzZ0w2S1o4bVd0dTAxZVBzQ05UTm9vWUxoSFc0UlpFMFRvVjJsMHNXbTdoeTNQZkdYRXlJWnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Believe Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are A Poor Guide For Its Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPSlg0NUxGb0FWRGZDd1lWWVBfVTI2dGpodU1aWElzQmtoaDBZaGduV2kxcEhuU0lxNHRSNjk0M3hhYWxiM2FRSjd1dGlGaHhoRUw0TVJRS1I5MTBNdGJCSVdvV3RycWFoTDlDZDFzdUJJbnVsWkJuWHhxWldlQno1QlpiZXZGU0Qtc3VDTXBMQkduRGNFTk4tVzBzRVpnalRJeFNzQkg1QXREQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rigel Pharmaceuticals (RIGL) Q1 EPS Compression Tests Bullish High\u2011Earnings Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) to Report Q1 Results: Wall Street Expects Earnings Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOTzRyQ3U5aXpndVdpbzJYM3otVmRSMWZjNV9fMWJEanpZWkM5THRfVFFKX1FUbnM2TmJEZEpQWWFVNUhLM1FSeUtZdElxd2RVcVhWaUt6UHZjSFBzVW4wUXB6S1h2b25PSDExVkZGdTdtaDJfWUwyVlJIajgxYXNORWp1Y2VlTlNZYVVCWnREaklfRlBTT0xUYURMUWNuSnhiVE1n?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Rigel Pharmaceuticals (RIGL) Valuation After Strong Q4 And Full Year 2025 Earnings Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-07T08:00:00+00:00", "published_display": "07 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharma stock slides on 2026 outlook (RIGL:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNeXQ0TXFCcldrU2lFR2JSN0ZfdHp1emp6UjFpMDV3Q2J1M1FObG1tSXJyQWxPNlNzQmU0WldXYlBHVENFTDVRelRtZzhkMGpCVWVPWTZ4ODB5S2NsbzQ2X2ZaVGM0eGZFcXZ5S0Jra25yR0ZYWGI5OUhDYU1xZ2llajBB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Rigel Pharmaceuticals (RIGL) Story Is Shifting With New Targets And Pipeline Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPVUZYWFVSajZiY3o2M010Q3F5eDVjOVVETmhIS2h2ZTgtR3RjdHUxMFR1NmVUc0Y1VURpQ1RkOVBZY25hOXZhWnl3RXZhcDVqdHRmTkxNUEtrQnk1UEM0a0dnOVZfVkJmR2E2ajNJNTUyS2RqeFM0aHRUb1lUcV81cjFuSFpYY0VLSDdrakpPdGQ?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNT2lyMmVxZmdnV0NvRVppTjFDaG40aEdNTkFjN2w1NWx3dGE5Zm5hcGVnTkFjemU4Vm0xNTU4aDJoQUxmVHlNNU82VjQtQWRQSGV3XzVrTnpXR0pWYXlNM3hyYzU1X3M3Z01OTnpmTk1ocmR1YzRpNmNRMG9DNlkwR1V0amlmQldmMUI0eA?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Narrative Around Rigel Pharmaceuticals (RIGL) Is Shifting With Raised Guidance And Cash Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOZzI4U2NYbU9fWlZjbWZickhlUXQxbTlWSzVLVHRlQzdTaGlWMVFKc0hyMFR1VVFoNm5oUl9rakhQMU9wa1RzOGFqcWZhSXppUW9tYzJoRVlRaEZlSXkyeGdGaDlMMVFIZ05iVE9RWXk0QWRWaVdXc2wxNXlzVWc2Nmt0TU41ODNmQnNYamdyMTR2Zlk?oc=5", "source_name": "Market source", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 68, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Common Stock (RIGL) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE8zYUpUalBOenFLX3lPVEtqdkY2LS1kY0RRc0VGWGt1Y3FFM3NFMnFOWnNzWEI4Sk5Qemo5LWNsOUZ0M0FVNTBNTmsyc3ItSENkNk1WLXgwMA?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T02:21:28+00:00", "published_display": "13 Jan 2026 02:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Analysts Say The Rigel Pharmaceuticals (RIGL) Story Is Shifting After Q3 And 2025 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOY0R5TklSYVlwa0RLRWZ4bWtLcDAxWXJjNUk3QnlQWVZ5VUJzTmEzV3NzWTJnSmpJUjBfLWx0ejQtY0NqWTMyRS1pQVgxRW1WS0hHRmFmdzA1dDJJSUl0aHpsZUtpNUpibkdlMjBzZlUteGhOS013N3NreWxLTWU3QnVGNzkxTWtnbEdHdFR3?oc=5", "source_name": "Market source", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Who Sold Rigel Pharmaceuticals Made The Right Call As Market Cap Slides By US$97m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Price Is Right But Growth Is Lacking After Shares Rocket 35%", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxQcjRVYTUwY1hDRGIzQ3kwcEZqSjFkSXRacllOcDlpa1lHd3ZsN2E5dzVlWERkeGswU29fb0dFZlMtc1NXT0RiNElXcGRlMXJrZHItRm5IanhoVFh0M0xxbENESmM0Zk1DaUdLRUlnV2xOYUZiM2JkRHJnaWJxZnVvMlZqcklzYXFtSm9EeE1uREV2TzFxcEhNcWtnZzBhckg2ekZnclU1am96VDBlRGdWTW42ajRKNFNjMEFUYTNXakNTaTdfaWxDV25fOG1sSEFmQk5abW1uOXl5U0NGZDN0V002WHp6cWxfNUhj0gHwAUFVX3lxTE9JWnZhNUc3OUl1eUVtOEFVNkNwTHdEdU1GQV9zOFpHRFlxRld3MWxwZ1B5S3pVU1BSMThTQWt3cXotT3FoWnZja2ZjaU1mbkw0bTk0eGlybHhneVF0Tm5SRnVlQWVPeHZNWFhoRGhXR3hqU29iSDJOSTRwelNNdmp1RWhGejRLX3AwTTUwUDh4NzQyM1E2eGhCOV9tZnYzQjlZNjVQc1NzSHdVY3NZRm9EaElBRTdQZTlKTTR4eUxlREVZUmxPSElFNEtTZ3hyUk5DWnlXdFlHOFRXT2dzdWFCejQta0tTNUgwdmhISDhzNg?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors have a lot riding on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) with 65% ownership", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-24T07:00:00+00:00", "published_display": "24 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQaUl0VEFNeThOTThJcVFkTXM3VW9TYzVnNTVDakwxcTN2N0Z0aTl3clZqd1VYVlJfbmdTTjlBcjFJRkpRbElSdXhnWUtPZ3JrTGZ1UTBPM2ozOVdyMU9UanpMU1ZIOWRoa1VObnYtT0tZMjRGTkJIMGdGZzZ0NnVKekRrMFlZbi1LeGpxTWFSRF8zNDlHMEI0S2JB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-20T11:44:13+00:00", "published_display": "20 Jun 2026 11:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (RIGL) Price Events", "summary": "This article from Stock Traders Daily analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models to provide trading strategies and signals. It details key findings including sentiment analysis, risk-reward scenarios, and support/resistance levels across different time hor", "url": "https://news.stocktradersdaily.com/news_release/149/Liquidity_Mapping_Around_RIGL_Price_Events_062026011402_1781932442.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T01:14:00", "published_display": "20 Jun 2026 01:14", "sentiment": "positive", "sentiment_pct": 75, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Expands Oncology Portfolio with VEPPANU Global Rights", "summary": "Rigel Pharmaceuticals has acquired exclusive global rights for VEPPANU (vepdegestrant) through an agreement with Arvinas, Inc. and Pfizer Inc. This $70 million upfront payment expands Rigel's oncology pipeline. While analysts rate RIGL stock a \"Buy\" with a $57.00 target, TipRanks", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RIGL-Q/pressreleases/2546395/rigel-expands-oncology-portfolio-with-veppanu-global-rights/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T12:38:57", "published_display": "19 Jun 2026 12:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Rigel Pharmaceuticals Inc (RIGL), noting its strong financial status and high operating efficiency. The company's current financial score is 7.99, placing it well within the pharmaceuticals industry. Rigel recently reported a 1", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rigl/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:39", "published_display": "18 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey reports on Rigel Pharmaceuticals Inc (RIGL), noting its current stock price, market capitalization, and P/E ratio. The primary focus of the article is the company's revenue breakdown; however, it states that relevant data for business segments, region", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rigl/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T14:10:48", "published_display": "17 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart\u2013Scott\u2013Rodino Antitrust Improv", "summary": "Arvinas Holding Company LLC, Pfizer, and Rigel Pharmaceuticals have received approval under the Hart\u2013Scott\u2013Rodino Antitrust Improvements Act on June 11, 2026. This approval removes regulatory hurdles for their previously announced licensing agreement, allowing them to advance the", "url": "https://www.bitget.com/amp/news/detail/12560605463270", "source_name": "Bitget", "published_at": "2026-06-16T23:10:48", "published_display": "16 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Closes Licensing Deal for Breast Cancer Drug Veppanu", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rigel-pharmaceuticals-closes-licensing-deal-203103036.html", "source_name": "MT Newswires", "published_at": "2026-06-16T20:31:03+00:00", "published_display": "16 Jun 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel pays $70M for rights to FDA-approved breast cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPcTZocVRjX2dsT0w4cG4zbkZCUlZkNldScURUZ29tMFF2MmFDaFlpQjNvcDA0TlBIaGxwM3dsTGxZTWZCZFMxQUhWTFdrOVJpMi1hcWdlY2lkeE03LUxXQUxQVGQ2MWJxcF8zOUc3VGtMa3lSaEx3dXdTUnlJbldVNExob25QUWJkNVJKZFc5OHluVU5ocUxYOElfRXJIRjFzZko3bDJQQjBpNmlUQlJ5UWUyZDBSQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T20:01:00+00:00", "published_display": "16 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Announces Closing of Licensing Agreement for VEPPANU\u2122 (vepdegestrant)", "summary": "Rigel Pharmaceuticals, Inc. announced the closing of its licensing agreement for VEPPANU\u2122 (vepdegestrant) with Arvinas, Inc. and Pfizer Inc. The agreement, effective as of June 11, 2026, followed the early termination of the Hart-Scott Rodino waiting period. Rigel made an upfront", "url": "https://www.prnewswire.com/news-releases/rigel-announces-closing-of-licensing-agreement-for-veppanu-vepdegestrant-302802278.html", "source_name": "PR Newswire", "published_at": "2026-06-16T20:10:31", "published_display": "16 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (RIGL) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) stock, highlighting a neutral near and mid-term outlook but a strong long-term positive bias. It presents several AI-generated trading strategies, including long, momentum breakout, and short options, along with key ", "url": "https://news.stocktradersdaily.com/news_release/151/Why_RIGL_Price_Action_Is_Critical_for_Tactical_Trading_060926120602_1780977962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-09T00:06:00", "published_display": "09 Jun 2026 00:06", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel Pharmaceuticals", "summary": "Dean Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals, exercised stock options worth $52,271 for 3,381 shares. The company shows positive revenue growth of 10.28% and a high gross margin of 92.17%, but struggles with a high debt-to-equity ratio of 0.11. The article", "url": "https://www.benzinga.com/insights/news/26/06/53004684/insider-move-dean-schorno-exercises-options-realizing-52k-at-rigel-pharmaceuticals", "source_name": "Benzinga", "published_at": "2026-06-04T15:09:09", "published_display": "04 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGEL (RIGL) EVP Furey uses 877 shares to cover tax obligations", "summary": "RIGEL PHARMACEUTICALS INC EVP Raymond J. Furey reported a tax-withholding disposition of 877 common shares on June 1, 2026, at $29.86 per share to cover tax obligations. This non-market transaction is classified as a routine tax-withholding disposition, not a discretionary sale. ", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-411113e66737.html", "source_name": "Stock Titan", "published_at": "2026-06-04T06:10:28", "published_display": "04 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (NASDAQ: RIGL) EVP uses shares to cover tax obligations", "summary": "Rigel Pharmaceuticals EVP and Chief Commercial Officer, David A. Santos, reported a tax-related share disposition. He delivered 874 shares of common stock at $29.86 per share to cover tax obligations, which is a routine tax-withholding event, not an open-market sale. After this t", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-52243dba54e5.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:40:59", "published_display": "03 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (RIGL) CMO uses 850 shares to cover stock tax liability", "summary": "Rigel Pharmaceuticals Inc.'s EVP and Chief Medical Officer, Lisa Rojkjaer, disposed of 850 shares of common stock on June 1, 2026, to cover a tax liability. This transaction, valued at $29.86 per share, was a tax-withholding disposition, not an open-market sale or purchase. After", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-3f0e77093995.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:40:59", "published_display": "03 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) CFO exercises options and withholds shares for taxes", "summary": "Rigel Pharmaceuticals' EVP & Chief Financial Officer, Dean L. Schorno, exercised stock options for 3,381 shares and withheld 928 shares to cover tax obligations. This transaction was a tax-withholding event, not an open-market sale, leaving him with 78,790 directly held shares. A", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-cdac36f714e3.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:40:59", "published_display": "03 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake", "summary": "RIGEL PHARMACEUTICALS INC CEO Raul R. Rodriguez reported a Form 4 transaction where 2,424 shares of Common Stock were delivered on June 1, 2026, at $29.86 per share to cover tax obligations. This disposition is classified as routine tax withholding, not an open-market trade. Foll", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-1f5e715e5c76.html", "source_name": "Stock Titan", "published_at": "2026-06-03T21:40:59", "published_display": "03 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (NasdaqGS:RIGL) Stock Forecast & Analyst Predictions", "summary": "Rigel Pharmaceuticals (RIGL) is facing a forecast decline in earnings (33.2% per annum) and EPS (43.2% per annum) over the next three years, despite expected annual revenue growth of 6.9%. The company recently acquired global rights to the breast cancer therapy VEPPANU, which is ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rigl/rigel-pharmaceuticals/future", "source_name": "Simply Wall Street", "published_at": "2026-06-02T07:39:34", "published_display": "02 Jun 2026 07:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGL - Expansion And Clinical Pipeline Will Drive Future Opportunities Despite Risks", "summary": "Rigel Pharmaceuticals' future opportunities are driven by the expansion of its commercial portfolio and a diversified clinical pipeline, despite risks from product dependence and competition. Analysts have lifted their price target due to updated assumptions around long-term reve", "url": "https://simplywall.st/narratives/86r9h1hu-expansion-and-clinical-pipeline-will-drive-future-opportunities-despite-risks-3puf?bpId=4467656&link_type=cta_narrative_prompt_after_quote", "source_name": "Simply Wall Street", "published_at": "2026-05-29T20:10:00", "published_display": "29 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) director sells 2,500 shares in open-market trade", "summary": "Rigel Pharmaceuticals director Ali-Jackson Kamil sold 2,500 shares of common stock at an average price of $29.17 per share on May 26, 2026. This open-market transaction falls under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following the sale, the director ", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-5cd7f5724ada.html", "source_name": "Stock Titan", "published_at": "2026-05-29T02:39:45", "published_display": "29 May 2026 02:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Phar", "summary": "Kamil Ali-jackson, a Director at Rigel Pharmaceuticals Inc (RIGL), sold 2,500 shares of the company on May 26, 2026, reducing her holdings to 12,625 shares. This sale is part of a trend with no insider buys and two insider sells for RIGL over the last year. The stock is currently", "url": "https://www.gurufocus.com/news/8889885/insider-sell-kamil-alijackson-sells-2500-shares-of-rigel-pharmaceuticals-inc-rigl", "source_name": "GuruFocus", "published_at": "2026-05-29T02:39:45", "published_display": "29 May 2026 02:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (RIGL)", "summary": "Quantitative analysis for Rigel Pharmaceuticals Inc. (RIGL) shows strong sentiment across all horizons, supporting an overweight bias. The article details three trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, and stop-loss levels, ind", "url": "https://news.stocktradersdaily.com/news_release/8/Understanding_Momentum_Shifts_in_RIGL_052826103602_1780022162.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-28T22:39:45", "published_display": "28 May 2026 22:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock", "summary": "Rigel Pharmaceuticals director Ali-Jackson Kamil sold 2,500 shares of the company's common stock for a total of $72,925 on May 26, 2026. This transaction was conducted under a pre-arranged 10b5-1 trading plan. The company recently reported a 26% revenue increase in Q1 2026 and se", "url": "https://www.investing.com/news/insider-trading-news/rigel-pharmaceuticals-director-alijackson-kamil-sells-72925-in-stock-93CH-4715431", "source_name": "Investing.com", "published_at": "2026-05-28T20:39:45", "published_display": "28 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) CEO to Present at Jefferies Global Healthcare Conference", "summary": "Rigel Pharmaceuticals (RIGL) CEO, Raul Rodriguez, will present at the Jefferies Global Healthcare Conference on June 3, 2026, to highlight the company's advancements in biotechnology. While the stock is currently slightly overvalued according to its GF Value, its GF Score of 78 i", "url": "https://www.gurufocus.com/news/8886111/rigel-pharmaceuticals-rigl-ceo-to-present-at-jefferies-global-healthcare-conference", "source_name": "GuruFocus", "published_at": "2026-05-27T20:10:22", "published_display": "27 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel to Present at the Jefferies Global Healthcare Conference", "summary": "Rigel Pharmaceuticals, Inc. announced that its President and CEO, Raul Rodriguez, will present a company overview at the Jefferies Global Healthcare Conference. The presentation is scheduled for Wednesday, June 3, 2026, at 8:45 a.m. ET in New York. A live webcast and archived rec", "url": "https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-global-healthcare-conference-302782544.html", "source_name": "PR Newswire", "published_at": "2026-05-27T12:09:46", "published_display": "27 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech CEO to give Rigel company overview at Jefferies healthcare conference", "summary": "Rigel Pharmaceuticals (Nasdaq: RIGL) announced that its President and CEO, Raul Rodriguez, will present a company overview at the Jefferies Global Healthcare Conference on June 3, 2026, in New York. The presentation will be webcast live and available for replay on Rigel's investo", "url": "https://www.stocktitan.net/news/RIGL/rigel-to-present-at-the-jefferies-global-healthcare-ujsko29u2p65.html", "source_name": "Stock Titan", "published_at": "2026-05-27T12:09:46", "published_display": "27 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] RIGEL PHARMACEUTICALS INC SEC Filing", "summary": "This article details an SEC Form 144 filing by RIGEL PHARMACEUTICALS INC (RIGL) regarding a proposed sale of securities. The filing indicates a sale of 2,500 common shares by an individual with an aggregate market value of $72,925.00, acquired through restricted stock vesting as ", "url": "https://www.stocktitan.net/sec-filings/RIGL/144-rigel-pharmaceuticals-inc-sec-filing-ec0529825ef2.html", "source_name": "Stock Titan", "published_at": "2026-05-26T14:40:13", "published_display": "26 May 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress", "summary": "Rigel Pharmaceuticals, Inc. announced upcoming oral and poster presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress, showcasing data for GAVRETO\u00ae (pralsetinib) and REZLIDHIA\u00ae (olutasidenib). The presentations will include final data from the Phase 3 AcceleRET-Lung c", "url": "https://www.prnewswire.com/news-releases/rigel-announces-oral-and-poster-presentations-at-the-2026-asco-annual-meeting-and-eha2026-congress-302779594.html", "source_name": "PR Newswire", "published_at": "2026-05-21T21:40:16", "published_display": "21 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer\u2019s VEPPANU License With Rigel Adds New Angle To PFE Story", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pfizer-veppanu-license-rigel-adds-051231627.html", "source_name": "Simply Wall St.", "published_at": "2026-05-21T05:12:31+00:00", "published_display": "21 May 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGEL (NASDAQ: RIGL) director receives 5,750-share Restricted Stock Unit grant", "summary": "RIGEL Pharmaceuticals Inc. director Alison L. Hannah received a grant of 5,750 Restricted Stock Units (RSUs) as a compensation-related award, not a market purchase. These RSUs, which represent common stock shares, will fully vest on the day before the company's next Annual Meetin", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-3797d04e0321.html", "source_name": "Stock Titan", "published_at": "2026-05-20T23:40:17", "published_display": "20 May 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. (RIGL) M&A Call - Slideshow (NASDAQ:RIGL) 2026-05-20", "summary": "Rigel Pharmaceuticals, Inc. published a slide deck in conjunction with an M&A call on May 20, 2026. This article was written by SA Transcripts, Seeking Alpha's team responsible for thousands of quarterly earnings call transcripts. The team aims to share new transcript-related dev", "url": "https://seekingalpha.com/article/4907281-rigel-pharmaceuticals-inc-rigl-m-and-a-call-slideshow?source=generic_rss", "source_name": "Seeking Alpha", "published_at": "2026-05-20T23:39:50", "published_display": "20 May 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (RIGL) investors back equity plan, ESPP and auditor at 2026 meeting", "summary": "Rigel Pharmaceuticals stockholders approved amendments to the 2018 Equity Incentive Plan and the 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares respectively for future grants and purchases. All three director nominees were elected to serve until the 2029 ann", "url": "https://www.stocktitan.net/sec-filings/RIGL/8-k-rigel-pharmaceuticals-inc-reports-material-event-f5e1088adc77.html", "source_name": "Stock Titan", "published_at": "2026-05-20T20:10:53", "published_display": "20 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (NASDAQ: RIGL) director awarded 5,750 RSUs vesting before annual meeting", "summary": "Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) director Michael Patrick Miller was granted 5,750 Restricted Stock Units (RSUs) as compensation, which will vest fully before the company's next Annual Meeting, provided he continues his service on the Board. This transaction, detailed in", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-2be0f5f35644.html", "source_name": "Stock Titan", "published_at": "2026-05-20T12:10:53", "published_display": "20 May 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rigel-pharmaceuticals-inks-breast-cancer-203107776.html", "source_name": "Benzinga", "published_at": "2026-05-15T20:31:07+00:00", "published_display": "15 May 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA\u2011Approved Breast Cancer Drug VEPPANU", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rigel-present-2026-rbc-capital-120500026.html", "source_name": "PR Newswire", "published_at": "2026-05-14T12:05:00+00:00", "published_display": "14 May 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rigel-pharmaceuticals-rigl-20-5-061326997.html", "source_name": "Simply Wall St.", "published_at": "2026-05-14T06:13:26+00:00", "published_display": "14 May 2026 06:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breast cancer drug VEPPANU shifts to Rigel in $85M Arvinas-Pfizer deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNcEZEeEw3bF9WMjhZRWZlWGVFMHFVWEtSSGcyUm9GaTQ2SmZMWkwtU2pDWDBzRVdWbVE2QVF5NTZFdFVBN3ZReTBPZ2szRmhFWThDcmR0RHNoQzE1U0Rwc3JfSkxkWTctcU9UR3JHeHJwc2dDamxUeVVzZ0w2S1o4bVd0dTAxZVBzQ05UTm9vWUxoSFc0UlpFMFRvVjJsMHNXbTdoeTNQZkdYRXlJWnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Believe Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are A Poor Guide For Its Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPSlg0NUxGb0FWRGZDd1lWWVBfVTI2dGpodU1aWElzQmtoaDBZaGduV2kxcEhuU0lxNHRSNjk0M3hhYWxiM2FRSjd1dGlGaHhoRUw0TVJRS1I5MTBNdGJCSVdvV3RycWFoTDlDZDFzdUJJbnVsWkJuWHhxWldlQno1QlpiZXZGU0Qtc3VDTXBMQkduRGNFTk4tVzBzRVpnalRJeFNzQkg1QXREQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Q1 EPS Compression Tests Bullish High\u2011Earnings Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) to Report Q1 Results: Wall Street Expects Earnings Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOTzRyQ3U5aXpndVdpbzJYM3otVmRSMWZjNV9fMWJEanpZWkM5THRfVFFKX1FUbnM2TmJEZEpQWWFVNUhLM1FSeUtZdElxd2RVcVhWaUt6UHZjSFBzVW4wUXB6S1h2b25PSDExVkZGdTdtaDJfWUwyVlJIajgxYXNORWp1Y2VlTlNZYVVCWnREaklfRlBTT0xUYURMUWNuSnhiVE1n?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Rigel Pharmaceuticals (RIGL) Valuation After Strong Q4 And Full Year 2025 Earnings Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-07T08:00:00+00:00", "published_display": "07 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharma stock slides on 2026 outlook (RIGL:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNeXQ0TXFCcldrU2lFR2JSN0ZfdHp1emp6UjFpMDV3Q2J1M1FObG1tSXJyQWxPNlNzQmU0WldXYlBHVENFTDVRelRtZzhkMGpCVWVPWTZ4ODB5S2NsbzQ2X2ZaVGM0eGZFcXZ5S0Jra25yR0ZYWGI5OUhDYU1xZ2llajBB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Rigel Pharmaceuticals (RIGL) Story Is Shifting With New Targets And Pipeline Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPVUZYWFVSajZiY3o2M010Q3F5eDVjOVVETmhIS2h2ZTgtR3RjdHUxMFR1NmVUc0Y1VURpQ1RkOVBZY25hOXZhWnl3RXZhcDVqdHRmTkxNUEtrQnk1UEM0a0dnOVZfVkJmR2E2ajNJNTUyS2RqeFM0aHRUb1lUcV81cjFuSFpYY0VLSDdrakpPdGQ?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNT2lyMmVxZmdnV0NvRVppTjFDaG40aEdNTkFjN2w1NWx3dGE5Zm5hcGVnTkFjemU4Vm0xNTU4aDJoQUxmVHlNNU82VjQtQWRQSGV3XzVrTnpXR0pWYXlNM3hyYzU1X3M3Z01OTnpmTk1ocmR1YzRpNmNRMG9DNlkwR1V0amlmQldmMUI0eA?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Narrative Around Rigel Pharmaceuticals (RIGL) Is Shifting With Raised Guidance And Cash Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOZzI4U2NYbU9fWlZjbWZickhlUXQxbTlWSzVLVHRlQzdTaGlWMVFKc0hyMFR1VVFoNm5oUl9rakhQMU9wa1RzOGFqcWZhSXppUW9tYzJoRVlRaEZlSXkyeGdGaDlMMVFIZ05iVE9RWXk0QWRWaVdXc2wxNXlzVWc2Nmt0TU41ODNmQnNYamdyMTR2Zlk?oc=5", "source_name": "Market source", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 68, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Common Stock (RIGL) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE8zYUpUalBOenFLX3lPVEtqdkY2LS1kY0RRc0VGWGt1Y3FFM3NFMnFOWnNzWEI4Sk5Qemo5LWNsOUZ0M0FVNTBNTmsyc3ItSENkNk1WLXgwMA?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T02:21:28+00:00", "published_display": "13 Jan 2026 02:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Analysts Say The Rigel Pharmaceuticals (RIGL) Story Is Shifting After Q3 And 2025 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOY0R5TklSYVlwa0RLRWZ4bWtLcDAxWXJjNUk3QnlQWVZ5VUJzTmEzV3NzWTJnSmpJUjBfLWx0ejQtY0NqWTMyRS1pQVgxRW1WS0hHRmFmdzA1dDJJSUl0aHpsZUtpNUpibkdlMjBzZlUteGhOS013N3NreWxLTWU3QnVGNzkxTWtnbEdHdFR3?oc=5", "source_name": "Market source", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Who Sold Rigel Pharmaceuticals Made The Right Call As Market Cap Slides By US$97m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Price Is Right But Growth Is Lacking After Shares Rocket 35%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors have a lot riding on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) with 65% ownership", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-24T07:00:00+00:00", "published_display": "24 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 62, "sentiment_summary": {"positive": 18, "negative": 5, "neutral": 39, "score": 55, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 9.29, "count": 18}, {"event": "guidance", "label": "Guidance", "weight": 3.1, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 18, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 32.91, "latest_week": "2026-06-19", "one_week_move": 0.2, "four_week_move": 13.4, "twelve_week_move": 27.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.369327, "market_dynamics_buy_signal": false, "relative_strength": -16.862314, "fair_value_gap": 59.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 51.243, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.2% over one week, +13.4% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 53, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "simplywall.st", "count": 11}, {"label": "Market source", "count": 11}, {"label": "PR Newswire", "count": 4}, {"label": "Seeking Alpha", "count": 3}, {"label": "Stock Traders Daily", "count": 3}, {"label": "TradingKey", "count": 2}, {"label": "Benzinga", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 18}, {"label": "Deals and strategy", "count": 5}, {"label": "Guidance", "count": 5}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.2% over one week, +13.4% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL)"}], "updated_at": "2026-06-22T05:12:25.275353+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}